Blockchain Registration Transaction Record

Onco-Innovations Partners with Nanosoft Polymers to Advance Cancer Drug ONC010

Onco-Innovations partners with Nanosoft Polymers to advance ONC010, a nanoparticle PNKP inhibitor for solid tumors. Collaboration focuses on scalable polymer production and GMP readiness for clinical trials.

This collaboration is crucial because it addresses a key bottleneck in drug development: scaling up nanoparticle manufacturing while maintaining quality. For patients, this means a promising new cancer therapy—ONC010, a PNKP inhibitor that targets solid tumors—could move faster toward clinical trials. For investors, it signals that Onco-Innovations is building a robust manufacturing and regulatory foundation, increasing the likelihood of successful IND submission and eventual commercialization. The partnership also strengthens the company's position in the competitive oncology landscape by leveraging specialized expertise to de-risk the development process.